AGMBNASDAQ Global Market· United States· Healthcare
This company scores below average, with supportive analyst views and a healthy balance sheet, although its current valuation deserves attention.
Quant Score on a 1–100 scale, computed Oct 29, 5:48 PM EDT from the data shown on this page. It describes the company’s current profile — it is not a price prediction or a recommendation. How it’s calculated
Tap any area to see the numbers it is based on.
The case for, the case against, and what to watch.
Is the business growing, profitable and able to carry its debt?
Is the stock reasonably priced?
The stock looks expensive relative to its earnings and cash flow, so expectations are high.
A formula-based estimate from projected cash flows. Small changes in assumptions move it a lot — treat it as one input, not a price the stock will reach.
Range $35.00–$35.00. Analysts' 12-month opinions; they are frequently wrong and are not our forecast.
See how it stacks up on quality, growth, valuation, risk and momentum.
Is this a profitable, well-run business?
Weak. Strongest signal: free cash flow / operating cash flow at 100%. Weakest: return on equity (ttm) at -19.7%.
| Input | Value | Points /10 |
|---|---|---|
| Return on equity (TTM) | -19.7% | 0.0 |
| Return on invested capital (TTM) | -11.8% | 0.0 |
| Operating margin (TTM) | 0.0% | 0.0 |
| Net margin (TTM) | 0.0% | 0.0 |
| Free cash flow / operating cash flow | 100% | 10.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Is this a financially healthy business?
Strong. Strongest signal: debt / equity at 0.00. Weakest: interest coverage at -257.1x.
| Input | Value | Points /10 |
|---|---|---|
| Piotroski F-Score | — | n/a |
| Altman Z-Score | — | n/a |
| Debt / Equity | 0.00 | 10.0 |
| Current ratio | 12.9x | 10.0 |
| Interest coverage | -257.1x | 0.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Is the stock expensive?
Expensive.
| Input | Value | Points /10 |
|---|---|---|
| P/E (TTM) | -9.0x | 0.0 |
| PEG | -0.09 | n/a |
| Price / FCF | -13.1x | n/a |
| EV / EBITDA | -3.6x | n/a |
| DCF upside | -76.2% | 0.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Is the company growing?
Slow or shrinking.
| Input | Value | Points /10 |
|---|---|---|
| Revenue growth (FY) | — | n/a |
| Net income growth (FY) | -35.2% | 0.0 |
| Revenue CAGR (3Y) | — | n/a |
| Forward revenue growth | — | n/a |
| Gross margin | 0.0% | 0.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Is the stock price showing strength?
Weak. Strongest signal: macd histogram at 0.07. Weakest: trend alignment (50/200 sma) at 0/3.
| Input | Value | Points /10 |
|---|---|---|
| Trend alignment (50/200 SMA) | 0/3 | 0.0 |
| RSI (14) | 32.5 | 2.0 |
| MACD histogram | 0.07 | 10.0 |
| Signal consensus | Sell | 3.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
What do professional analysts think?
Very positive. Strongest signal: target upside at 340.3%.
| Input | Value | Points /10 |
|---|---|---|
| Analyst buy share | — | n/a |
| Target upside | 340.3% | 10.0 |
| 90-day rating revisions | 0↑ / 0↓ | n/a |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
What could go wrong?
High risk. Weakest: price volatility (1y, annualised) at 92%.
| Input | Value | Points /10 |
|---|---|---|
| Beta (vs. market) | 1.80 | 1.5 |
| Price volatility (1Y, annualised) | 92% | 0.0 |
| Largest 1Y drawdown | -55% | 0.0 |
| Net debt / EBITDA | 6.2x | 0.0 |
“n/a” means the data wasn’t available; missing inputs are left out of the average, never counted as zero.
Source: Financial Modeling Prep · P/E trailing twelve months; history from annual filings · USD · data as of Oct 24, 2026
Revenue is what customers paid the company. It has been negative over the period shown.
Net income is the profit left after all costs and taxes. It has been negative over the period shown.
Cash the business generates after investing in itself — what can fund dividends, buybacks or growth. There isn't enough history to see a trend.
Share of sales left after the direct cost of products.
Share of sales left after running the business.
Share of sales kept as profit.
Debt is low compared with shareholders' equity.
Returns on invested money are low.
Profits only just cover interest payments.
Source: Financial Modeling Prep · annual filings FY2022–FY2025; margins and ratios trailing twelve months · USD · data as of Oct 24, 2026
